Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P30536 (
PBS
)
9,886
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Corticotropin releasing factor (CRF) binding protein (
CRF-BP
) was measured in media and cell lysates of primary rat astrocytes, microglia and neurons with the use of a ligand immunoradiometric assay (LIRMA). A low basal level of
CRF-BP
was detected in the media and cell lysates from primary neuronal and astrocyte cells after 48 h in culture. No basal expression of
CRF-BP
was detected in cell lysates or media from primary microglial cultures. The
CRF-BP
expressed in cultured astrocytes and neurons had the same pharmacological characteristics as the human recombinant molecule. After forskolin, IBMX or forskolin/IBMX treatment, a robust increase in secreted
CRF-BP
levels in the media from astrocytes and neurons, but not microglia, was observed. An increase in
CRF-BP
-like immunoreactivity in cell lysates was also observed after IBMX/forskolin treatment. In situ hybridization analysis revealed that
CRF-BP
mRNA was increased in primary cultured astrocytes after IBMX/forskolin stimulation suggesting that regulation was at the level of gene transcription. 'Axon sparing' lesions produced with 0.12 M quinolinic acid in
PBS
injected intracerebrally (unilaterally into dorsal hippocampus) resulted in loss of
CRF-BP
expression in neurons. These data provide evidence for the differential localization and regulation of
CRF-BP
in different cell types in brain and suggest that
CRF-BP
expression may be locally increased in disease states associated with astrocytosis and gliosis.
...
PMID:Corticotropin releasing factor binding protein (CRF-BP) is expressed in neuronal and astrocytic cells. 858 94